
## Nicole Praschak-rieder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1252971/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Elevated Monoamine Oxidase A Levels in the Brain. Archives of General Psychiatry, 2006, 63, 1209.	12.3	507
2	Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference. Neuropsychopharmacology, 2003, 28, 734-739.	5.4	307
3	Seasonal Variation in Human Brain Serotonin Transporter Binding. Archives of General Psychiatry, 2008, 65, 1072.	12.3	224
4	Bright-Light Therapy in the Treatment of Mood Disorders. Neuropsychobiology, 2011, 64, 152-162.	1.9	205
5	Association Between Serotonin Transporter Gene Promoter Polymorphism(5HTTLPR) and Behavioral Responses to Tryptophan Depletion in Healthy Women With and Without Family History of Depression. Archives of General Psychiatry, 2002, 59, 613.	12.3	193
6	Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study. Biological Psychiatry, 2007, 62, 327-331.	1.3	186
7	[123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biological Psychiatry, 2000, 47, 482-489.	1.3	185
8	Lithium in drinking water and suicide mortality. British Journal of Psychiatry, 2011, 198, 346-350.	2.8	142
9	[123I] β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biological Psychiatry, 2001, 49, 326-332.	1.3	134
10	No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biological Psychiatry, 2001, 50, 8-12.	1.3	117
11	Direct Effect of Sunshine on Suicide. JAMA Psychiatry, 2014, 71, 1231.	11.0	117
12	A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Molecular Psychiatry, 2003, 8, 942-946.	7.9	103
13	Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology, 2007, 190, 575-579.	3.1	99
14	Reduced default mode network suppression during a working memory task in remitted major depression. Journal of Psychiatric Research, 2015, 64, 9-18.	3.1	99
15	Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychological Medicine, 2001, 31, 1467-1473.	4.5	97
16	Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans. Biological Psychiatry, 2005, 58, 825-830.	1.3	92
17	Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder. Neuropsychopharmacology, 2008, 33, 1503-1513.	5.4	85
18	lmaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. NeuroImage, 2010, 53, 878-892.	4.2	82

#	Article	IF	CITATIONS
19	Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology World Journal of Biological Psychiatry, 2002, 3, 133-146.	2.6	80
20	Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [1231]-2l²-carbomethoxy-3l²- (4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry, 2000, 47, 158-160.	1.3	70
21	Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy. Biological Psychiatry, 2005, 58, 331-336.	1.3	69
22	Monoaminergic function in the pathogenesis of seasonal affective disorder. International Journal of Neuropsychopharmacology, 2001, 4, 409-20.	2.1	63
23	Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychological Medicine, 1998, 28, 257-264.	4.5	61
24	A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression. Drug Safety, 1997, 17, 251-264.	3.2	60
25	Effects of sunshine on suicide rates. Comprehensive Psychiatry, 2012, 53, 535-539.	3.1	60
26	Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans. Journal of Neuroscience, 2014, 34, 9917-9926.	3.6	59
27	Effects of Tryptophan Depletion in Drug-Free Depressed Patients Who Responded to Total Sleep Deprivation. Archives of General Psychiatry, 1998, 55, 167.	12.3	58
28	Suicidal Tendencies as a Complication of Light Therapy for Seasonal Affective Disorder. Journal of Clinical Psychiatry, 1997, 58, 389-392.	2.2	56
29	Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. Journal of Affective Disorders, 2001, 63, 239-242.	4.1	50
30	Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. American Journal of Psychiatry, 1997, 154, 1153-1155.	7.2	46
31	Making Sense of: Sensitization in Schizophrenia. International Journal of Neuropsychopharmacology, 2017, 20, 1-10.	2.1	44
32	Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor–treated depression: An [18F] MPPF positron emission tomography study. Biological Psychiatry, 2004, 56, 587-591.	1.3	40
33	Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. European Neuropsychopharmacology, 2002, 12, 129-134.	0.7	38
34	C825T polymorphism in the G protein β3-Subunit gene is associated with seasonal affective disorder. Biological Psychiatry, 2003, 54, 682-686.	1.3	38
35	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. Psychological Medicine, 2003, 33, 785-792.	4.5	37
36	Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene?. Psychiatry Research, 1999, 85, 241-246.	3.3	34

NICOLE PRASCHAK-RIEDER

#	Article	IF	CITATIONS
37	Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 54-62.	3.2	33
38	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. Brain Structure and Function, 2016, 221, 103-114.	2.3	31
39	Reboxetine in seasonal affective disorder: an open trial. European Neuropsychopharmacology, 2001, 11, 1-5.	0.7	30
40	Seasonality of Birth in Seasonal Affective Disorder. Journal of Clinical Psychiatry, 2004, 65, 1389-1393.	2.2	29
41	Escitalopram in Seasonal Affective Disorder: Results of an Open Trial. Pharmacopsychiatry, 2007, 40, 20-24.	3.3	28
42	Seasonal affective disorder and the G-protein β-3-subunit C825T polymorphism. Biological Psychiatry, 2004, 55, 317-319.	1.3	26
43	Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. European Neuropsychopharmacology, 2015, 25, 2183-2184.	0.7	26
44	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry, 2020, 10, 2.	4.8	25
45	Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label Study. Pharmacopsychiatry, 2008, 41, 100-105.	3.3	24
46	Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence. Current Pharmaceutical Design, 2012, 18, 1568-1579.	1.9	24
47	Treatment of seasonal affective disorders. Dialogues in Clinical Neuroscience, 2003, 5, 389-398.	3.7	23
48	Imaging of Seasonal Affective Disorder and Seasonality Effects on Serotonin and Dopamine Function in the Human Brain. Current Topics in Behavioral Neurosciences, 2011, 11, 149-167.	1.7	22
49	Mirtazapine in seasonal affective disorder (SAD): a preliminary report. Human Psychopharmacology, 1999, 14, 59-62.	1.5	21
50	Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. Journal of Psychiatric Research, 2009, 43, 792-797.	3.1	18
51	Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. European Neuropsychopharmacology, 2004, 14, 53-58.	0.7	17
52	Anger attacks in seasonal affective disorder. International Journal of Neuropsychopharmacology, 2006, 9, 215.	2.1	12
53	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. NeuroImage, 2020, 223, 117270.	4.2	11
54	A Cys23–Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian–Canadian collaborative study. Journal of Psychiatric Research, 2005, 39, 561-567.	3.1	8

NICOLE PRASCHAK-RIEDER

#	Article	IF	CITATIONS
55	Season of birth in siblings of patients with seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 378-382.	3.2	8
56	Monoamine Depletion in Non-Pharmacological Treatments for Depression. Advances in Experimental Medicine and Biology, 1999, 467, 29-33.	1.6	8
57	Serum lipid levels in seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 197-202.	3.2	7
58	Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World Journal of Biological Psychiatry, 2022, 23, 715-718.	2.6	6
59	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. Journal of ECT, 2017, 33, e31-e32.	0.6	5
60	Light Treatment in Depression(SAD, s-SAD & non-SAD). , 1999, , 409-416.		5
61	Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. European Journal of Neuroscience, 2017, 45, 45-57.	2.6	4
62	Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention. Current Medical Research and Opinion, 2009, 25, 2281-2285.	1.9	3
63	In Vivo Imaging of Dopamine Metabolism and Dopamine Transporter Function in the Human Brain. Neuromethods, 2016, , 203-220.	0.3	3
64	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal of Affective Disorders Reports, 2021, 5, 100186.	1.7	3
65	Severe Atypical Symptoms Without Depression in SAD. Journal of Clinical Psychiatry, 1997, 58, 495.	2.2	2
66	Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. International Journal of Neuropsychopharmacology, 2003, 6, 199-200.	2.1	1
67	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, 74-74.	2.1	1
68	Lichttherapie. , 2012, , 823-827.		0
69	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
70	Neuroimaging in Seasons and Winter Depression. , 2014, , 209-222.		0
71	Neuroimaging in Seasons and Winter Depression. , 2021, , 245-259.		0
72	Nichtpharmakologische somatische Therapien. , 2008, , 727-750.		0

5